Cannabidiol for spasms, infantile

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 2 Nov 2016: Trial registered, NCT02953548
  2. 4 Nov 2016: Trial registered, NCT02954887
  3. 24 Apr 2017: Trial started, NCT02953548
  4. 12 May 2017: Trial started, NCT02954887

The trials

NCT02953548: Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)

State
Completed
Phase
Phase 3
People
9 taking part
Started
24 Apr 2017
Primary completion
7 May 2018
Arms
GWP42003-P
Results
Posted on the registry
  1. 2 Nov 2016: Trial registered
  2. 24 Apr 2017: Trial started
  3. 7 May 2018: Trial completed
  4. 23 Jul 2020: Trial results posted

NCT02954887: Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)

State
Completed
Phase
Phase 3
People
9 taking part
Started
12 May 2017
Primary completion
13 Jun 2019
Arms
GWP42003-P
Results
Posted on the registry
  1. 4 Nov 2016: Trial registered
  2. 12 May 2017: Trial started
  3. 13 Jun 2019: Trial completed
  4. 23 Jul 2020: Trial results posted

NCT04485104: Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

State
Stopped early
Phase
Phase 3
People
3 taking part
Started
19 May 2021
Primary completion
28 Jan 2025
Arms
GWP42003-P
Results
Posted on the registry
  1. 24 Jul 2020: Trial registered
  2. 19 May 2021: Trial started
  3. 28 Jan 2025: Trial terminated
  4. 31 Oct 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Cardiolrx, Canapure PH, Cannabidiol (Epidiolex), Cannabidiol Oral Solution, Epidiolex, Epidiolex 100 mg/mL Oral Solution, Epidyolex, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose, GWP42003-P 5 mg/kg/day Dose, MediCabilis.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.